STOCK TITAN
  1. Home
  2. Sec-filings
  3. CV
  4. [8-K] CapsoVision, Inc Reports Material Event

CapsoVision (NASDAQ: CV) adds $100M ATM as Q2 losses widen and cash burns

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

CapsoVision, Inc. entered into a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market equity program under which it may sell up to $100,000,000 of common stock from time to time. Cantor will act as sales agent or principal for a commission of up to 3.0% of gross proceeds. The company plans to use a Form S-3 shelf registration and an at-the-market prospectus supplement for these potential issuances.

For the quarter ended June 30, 2026, CapsoVision reported revenue of $3.6 million, up about 10% year over year, driven by a 13% increase in CapsoCam Plus capsule volume, partly offset by lower average selling prices. Gross margin was 51%, down from 55% a year earlier due to pricing pressure and higher customs and tariff costs. Operating expenses rose to $9.5 million, mainly from clinical trials, development work and public company costs, leading to an operating loss of $7.6 million and a net loss of $7.5 million.

Cash and cash equivalents were $9.1 million as of June 30, 2026, with net cash used in operating activities of $14.5 million in the first half of 2026. Operationally, management highlighted international launch of its AI Highlights feature, broader hospital and GI network adoption, over 176,000 patients having used CapsoCam Plus, and pipeline progress including anticipated FDA clearance of AI Highlights by the end of the third quarter of 2026 and a planned 510(k) submission for CapsoCam Colon in the fourth quarter of 2026.

Positive

  • Revenue grew 10% year over year in Q2 2026 to $3.6 million, driven by a 13% increase in CapsoCam Plus capsule sales despite modest price pressure.
  • CapsoVision secured an at-the-market equity program of up to $100,000,000 with Cantor Fitzgerald, enhancing potential future access to capital.
  • Cash and cash equivalents totaled $9.1 million at June 30, 2026, supported by $14.0 million proceeds from a Private Placement during the first half of 2026.
  • The company reported strong strategic progress, including international launch of AI Highlights, over 176,000 patients using CapsoCam Plus, and clear regulatory timelines for AI Highlights and CapsoCam Colon.

Negative

  • Quarterly operating loss increased to $7.6 million from $4.7 million, as operating expenses rose to $9.5 million driven by clinical, development, and public company costs.
  • Net cash used in operating activities for the first half of 2026 was $14.5 million, a larger outflow than the $9.5 million used in the same period of 2025.
  • Gross margin declined to 51% from 55% year over year, pressured by competitive pricing and higher customs and tariff expenses.
  • The company remains loss-making, with a first-half 2026 net loss of $14.5 million compared with $10.0 million in the prior-year period.

Filing Explained

The agreement adds up to $100 million of potential issuance capacity, but this filing reports no shares sold or dilution yet.

The August 13 Form 8-K reports that CapsoVision entered an agreement allowing it to sell up to $100 million of common stock through Cantor; the agreement is not itself a completed sale.

Although the filing describes an offering of up to $100 million, sales remain at the company’s discretion, the company is not obligated to sell shares, and this filing reports no shares sold or proceeds received. Issuing shares would increase the share count and could reduce existing holders’ percentage ownership.

An at-the-market program permits gradual sales into the market at prevailing prices. CapsoVision also says it intends to file a Form S-3 and an at-the-market prospectus supplement; an S-3 would provide future registered-selling capacity, not itself sell shares.

The next specific milestones are the intended S-3 and prospectus-supplement filings and any later filing reporting sales under the agreement.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
ATM program size $100,000,000 Maximum aggregate offering price of common stock under Controlled Equity Sales Agreement with Cantor
Q2 2026 net revenue 3,643 (thousands of $) Net revenue for the three months ended June 30, 2026
Q2 2026 net loss 7,481 (thousands of $) Net loss for the three months ended June 30, 2026
Q2 2026 operating expenses 9,451 (thousands of $) Total operating expenses for the three months ended June 30, 2026
Cash and cash equivalents 9,077 (thousands of $) Cash and cash equivalents as of June 30, 2026
Net cash used in operations 14,469 (thousands of $) Net cash used in operating activities for the six months ended June 30, 2026
Shares outstanding 50,032,148 Common shares issued and outstanding as of June 30, 2026
Controlled Equity Sales Agreement financial
"entered into a Controlled Equity Sales Agreement (the “Sales Agreement”) with Cantor"
at-the-market offering financial
"with respect to an at-the-market offering program under which the Company may offer"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
gross margin financial
"Gross margin was 51%, compared to 55% in the second quarter of 2025."
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
510(k) submission regulatory
"CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026"
A 510(k) submission is a regulatory packet sent to the U.S. Food and Drug Administration showing a medical device is substantially similar to an already-allowed device so it can be marketed without a full, new safety review. For investors, clearance via 510(k) cuts time and cost to bring a device to market and reduces regulatory risk—think of it as proving a new model is close enough to a trusted one to sell it more quickly.
stock-based compensation financial
"driven primarily by expenses associated with the colon pivotal study and other clinical trials, non-recurring engineering services ... and stock-based compensation."
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
Private Placement financial
"Proceeds from Private Placement | 14,000"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Net revenue (Q2 2026) $3.6 million Increased from $3.3 million in Q2 2025
Gross margin (Q2 2026) 51% Decreased from 55% in Q2 2025
Operating loss (Q2 2026) $7.6 million Widened from $4.7 million in Q2 2025
Net loss (H1 2026) $14.5 million Compared with $10.0 million in the first half of 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What equity offering did CapsoVision (CV) put in place with Cantor Fitzgerald?
CapsoVision entered a Controlled Equity Sales Agreement with Cantor allowing at-the-market sales of up to $100,000,000 of common stock. Cantor will act as sales agent or principal and receive up to a 3.0% commission on gross sales proceeds.

How did CapsoVision’s (CV) revenue perform in the second quarter of 2026?
CapsoVision reported second quarter 2026 revenue of $3.6 million, up from $3.3 million a year earlier. Growth was mainly driven by a 13% increase in CapsoCam Plus capsule volume, partially offset by about a 3% decline in average selling price.

What were CapsoVision’s (CV) profitability and gross margin in Q2 2026?
CapsoVision posted a Q2 2026 net loss of $7.5 million and an operating loss of $7.6 million. Gross margin was 51%, down from 55% in Q2 2025 due to pricing pressure and increased customs and tariff-related expenses.

What is CapsoVision’s (CV) cash position and cash burn so far in 2026?
CapsoVision had $9.1 million in cash and cash equivalents as of June 30, 2026. Net cash used in operating activities totaled $14.5 million in the first half of 2026, partly offset by $14.0 million of proceeds from a Private Placement.

What regulatory milestones did CapsoVision (CV) outline for its AI and colon products?
CapsoVision expects FDA clearance of AI Highlights by the end of Q3 2026 with a subsequent U.S. launch. The company also plans a 510(k) submission for CapsoCam Colon in Q4 2026 and continues clinical work on CapsoCam UGI for pancreatic cancer detection.

How many patients have used CapsoVision’s CapsoCam Plus system?
CapsoVision reported that over 176,000 patients had used CapsoCam Plus as of June 30, 2026. This reflects growing adoption across large hospital systems and GI networks, supported by customer renewals and increasing traction with new customers.
FALSE000137832500013783252026-08-132026-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2026
_________________________
CapsoVision, Inc.
(Exact name of registrant as specified in its charter)
_________________________
Delaware001-4270520-3369494
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification Number)
18805 Cox Avenue, Suite 250
Saratoga, California
95070
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (408)-624-1488
n/a
(Former Name or Former Address, if Changed Since Last Report)
_________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol		Name of each exchange
on which registered
common stock, $0.001 par value per shareCVThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 1.01.           Entry into a Material Definitive Agreement.
On August 13, 2026, CapsoVision, Inc. (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 (the “Shares”) through or to Cantor as its “sales agent” or principal (the “Agent”).
Under the Sales Agreement, the Company will set the parameters for the sale of Shares, including the number of Shares to be issued, the time period during which sales are requested to be made, limitations on the number of Shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms of the Sales Agreement, the Agent may sell the Shares by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act, including without limitation sales made directly on The Nasdaq Capital Market (“Nasdaq”) or any other trading market for the Shares.
The Company is not obligated to sell any Shares under the Sales Agreement. The Company or the Agent may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. The Agent will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq.
The Company will pay the Agent a cash commission equal to up to 3.0% of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and has provided the Agent with customary indemnification and contribution rights.
The Sales Agreement will terminate upon the earlier of (i) the sale of all Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with the terms and conditions set forth therein.
The Company intends to file a Registration Statement on Form S-3, including an “at-the-market offering” prospectus supplement relating to the offer and sale of the Shares, pursuant to which the shares to be offered and sold under the Sales Agreement will be issued and sold, and will file a Current Report on Form 8-K relating to it shortly.



Item 2.02.           Results of Operations and Financial Condition.
On August 13, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release, dated August 13, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01           Financial Statements and Exhibits.
The following exhibits are being filed herewith:
Exhibit
No.		Description
10.1*
Controlled Equity OfferingSM Sales Agreement, dated August 13, 2026, by and between CapsoVision, Inc. and Cantor Fitzgerald & Co.
99.1
Press Release of CapsoVision, Inc, dated August 13, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Certain personally identifiable information of this exhibit has been omitted pursuant to Item 601(a)(6) of Regulation S-K.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CAPSOVISION, INC.
Date: August 13, 2026By:/s/ Kang-Huai (Johnny) Wang
Name:Kang-Huai (Johnny) Wang
TitleDirector, President and Chief Executive Officer


Exhibit 99.1
logo.jpg
CapsoVision Reports Second Quarter 2026 Financial Results
SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.
Recent Highlights
•Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.
•CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.
•Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system.
•Anticipate FDA clearance of AI Highlights™ by the end of the third quarter of 2026, with U.S. commercial launch expected shortly thereafter.
•Continued commercial momentum with expanding adoption across large hospital systems and GI networks, including key customer renewals and growing traction with new customers.
•Pipeline continues to advance with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026, with ongoing enrollment in the CapsoCam UGI clinical study for pancreatic cancer detection.
•Appointed David S. Shields, M.D., to the Board of Directors, effective July 1, 2026.
•Entered into a sales agreement of up to $100 million providing for an at-the-market equity offering program with Cantor.
Management Commentary
"The second quarter marked another important step in the evolution of CapsoVision as we advanced both our commercial execution and product innovation. We were pleased to launch AI Highlights™ internationally, providing physicians in Europe with an AI-assisted workflow solution that complements our CapsoCam Plus® platform and reinforces our long-term vision of integrated, AI-enabled capsule endoscopy," said Johnny Wang, President and Chief Executive Officer of CapsoVision.
"Commercially, we continue to see encouraging momentum across our business. Revenue growth was in line with our expectations, hospital network adoption continues to expand, and we are adding new customers who recognize the value of our panoramic capsule platform. We also continue to hear strong interest from customers awaiting the U.S. launch of AI Highlights™, which we now anticipate following FDA clearance expected this fall. As we look toward the second half of the year, we remain focused on executing against our commercial strategy while advancing our broader product pipeline."
Second Quarter 2026 Financial Results
Total revenue was $3.6 million compared to $3.3 million in the second quarter of 2025. The primary driver for the revenue growth was a 13% increase in the number of CapsoCam Plus capsules sold offset by a period-over-period decrease of approximately 3% in the average selling price.


Gross profit was 1.9 million, an increase of $0.1 million, or 3% compared to the second quarter of 2025. Gross margin was 51%, compared to 55% in the second quarter of 2025. The decrease was due to a pressure on selling prices we have when operating in a highly competitive market and changes the U.S. government made to the trade policies and tariffs at the beginning of the year resulting in an increase in expenses for customs and tariffs.
Operating expenses were $9.5 million, a $3.0 million increase from the second quarter of 2025, driven primarily by expenses associated with the colon pivotal study and other clinical trials, non-recurring engineering services for the Canon development project, expenses for operating as a public company, and stock-based compensation.
Cash and cash equivalents totaled $9.1 million as of June 30, 2026.
Conference Call and Webcast
CapsoVision will host a conference call today, August 13, 2026, at 4:30 p.m. ET to discuss its second quarter financial results. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 9178774, or from the webcast link on the Events page in the investor relations section of the company's website at www.capsovision.com.
To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “positioned”, “on track”, “anticipate(s)”, “intend(s)”, “plan(s)”, “believe(s)”, “potential”, “will”, “should”, “could”, “would”, “may”, “continue”, “remain”, “advancing”, “approach(ing)”, “planned”, “look forward”, or “target(ed)” and other words of similar meaning. Examples of these forward-looking statements include, but are not limited to, statements concerning possible or assumed future results of operations and financial position, including the Company’s expectations regarding the Company’s product and clinical development efforts, the timing and receipt of regulatory submissions and approvals , the Company’s plans, strategies and timing for its pipeline development (including the anticipated timing of FDA clearance of AI Highlights™ and its subsequent U.S. commercial launch, the continued development and anticipated 510(k) submission for CapsoCam Colon™, and the clinical study for CapsoCam® UGI in pancreatic cancer detection) and the success of the Company’s plans and strategies. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company’s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions (including competition in the capsule endoscopy market), the Company’s financial condition and the availability of cash and financing (including through the Company’s at-the-market equity offering program), the success of the Company’s product and clinical development efforts, the failure to receive regulatory clearance or approval, changes in U.S. trade policies, tariffs or other government regulations that could increase the Company’s costs or affect the Company’s supply chain, and the failure to adapt the Company’s products for new indications. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s most recent Form 10-K and Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.


Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231


CAPSOVISION, INC.
CONDENSED BALANCE SHEETS (UNAUDITED)
(in thousands, except par value and share amounts)

June 30, 2026December 31, 2025
ASSETS
Current Assets
Cash and cash equivalents$9,077 $10,112 
Accounts receivable, net2,265 2,498 
Inventory4,704 2,987 
Prepaid expenses and other current assets1,234 1,072 
Total current assets17,280 16,669 
Property and equipment, net562 611 
Operating lease right-of-use assets651 843 
Other long-term assets76 41 
TOTAL ASSETS$18,569 $18,164 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable$475 $1,143 
Accrued expenses and other current liabilities4,101 2,697 
Deferred revenue140 177 
Operating lease liabilities – current442 410 
Total current liabilities5,158 4,427 
Operating lease liabilities – long-term245 477 
Total liabilities5,403 4,904 
Commitments and contingencies - Note 8
Stockholders’ Equity
Preferred stock, $0.001 par value: 10,000,000 shares authorized and none issued and outstanding as of June 30, 2026; 10,000,000 shares authorized and none issued and outstanding as of December 31, 2025
— — 
Common stock, $0.001 par value: 300,000,000 shares authorized as of June 30, 2026; 50,032,148 and 46,865,051 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
50 47 
Additional paid-in capital183,295 168,878 
Accumulated deficit(170,179)(155,665)
Total stockholders’ equity13,166 13,260 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$18,569 $18,164 

CAPSOVISION, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
(in thousands, except share and per-share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2026202520262025
Net revenue$3,643 $3,315 $6,435 $6,098 
Costs of revenue1,772 1,504 $3,235 $2,793 
Gross profit1,871 1,811 — 3,200 3,305 
OPERATING EXPENSES
Selling and marketing1,936 1,847 4,027 3,808 
Research and development5,309 3,392 9,744 6,499 
General and administrative2,206 1,223 4,102 3,031 
Total operating expenses9,451 6,462 17,873 13,338 
Operating loss(7,580)(4,651)(14,673)(10,033)
NON-OPERATING INCOME
Interest income, net82 37 141 43 
Other non-operating income (expense), net17 (11)18 (10)
Total non-operating income, net99 26 159 33 
Loss before income taxes(7,481)(4,625)(14,514)(10,000)
Provision for income taxes— — — — 
Net loss and comprehensive loss$(7,481)$(4,625)$(14,514)$(10,000)
Net loss per share – basic and diluted $(0.15)$(2.02)$(0.30)$(4.49)
Weighted average common shares outstanding – basic and diluted49,937,525 2,292,230 48,704,069 2,225,301 

CAPSOVISION, INC.
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
Six Months Ended June 30,
20262025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss$(14,514)$(10,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization114 107 
Loss on disposal of property and equipment— — 
Amortization of operating lease right-of-use assets192 171 
Unrealized foreign exchange losses (gains)15 (158)
Stock-based compensation911 322 
Bad debt expense— 11 
Changes in operating assets and liabilities:
Accounts receivable245 167 
Inventory(1,717)(413)
Prepaid expenses and other current assets(162)(939)
Other long-term assets(35)— 
Accounts payable(685)408 
Accrued expenses and other current liabilities1,404 1,019 
Deferred revenue(37)(35)
Operating lease liabilities(200)(172)
Net cash used in operating activities$(14,469)$(9,512)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment(48)(70)
Net cash used in investing activities $(48)$(70)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory note issuance— 1,000 
Proceeds from Private Placement14,000 — 
Payment of Private Placement issuance costs(600)— 
Payment of constructive dividend(12)— 
Proceeds from exercises of options on common stock and warrants121 202 
Net cash provided by financing activities$13,509 $1,202 
Net decrease in cash and cash equivalents(1,008)(8,380)
Effect of exchange rate changes on cash and cash equivalents(27)127 
Cash and cash equivalents at beginning of period10,112 9,319 
Cash and cash equivalents at end of period$9,077 $1,066 
SUPPLEMENTAL CASH FLOW DISCLOSURES
Cash paid for income taxes$11 $7 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Agreements & Contracts

Other Documents